Authorized purpose: The SOMATOM go and SOMATOM X platform CT systems with SOMARIS/10 syngo CT VB10 generate and process cross-sectional images from X-ray transmission data for trained staff to use as an aid in diagnosis, treatment and radiation therapy planning, and diagnostic or therapeutic interventions; the systems may also be used for low-dose lung cancer screening in high-risk populations.
Clinical role
CT patient positioning and acquisition, image reconstruction, image evaluation, and optional post-processing support within diagnosis, treatment planning, radiation therapy planning, and intervention workflows.
Images and patients
CT/CTA · Whole body
Key limitation
Keep in mind: The CT systems are not the principal means of guidance during invasive procedures, and needle orientation and advancement remain under physician control. Optional advanced-visualization applications require their own cleared standalone version, and feature availability varies across scanner models and configurations.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: The SOMATOM go and SOMATOM X platform CT systems with SOMARIS/10 syngo CT VB10 generate and process cross-sectional images from X-ray transmission data for trained staff to use as an aid in diagnosis, treatment and radiation therapy planning, and diagnostic or therapeutic interventions; the systems may also be used for low-dose lung cancer screening in high-risk populations.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Whole body Input: X-ray transmission data acquired on the listed SOMATOM go and SOMATOM X single-source CT scanner systems; supported options include three-dimensional camera data for patient positioning and external respiratory trigger signals for specified workflows.
Who uses it?Intended users: Trained and qualified users in professional healthcare facilities, including physicians, radiologists, and technologists; diagnosis or treatment requires appropriately qualified U.S. users.
What does the software produce?Output: Reconstructed cross-sectional CT images in DICOM format for qualified-user review and compatible optional post-processing applications; supported features include positioning, reconstruction, image-evaluation, and intervention workflow outputs depending on system configuration.
What is its most important limitation?Key limitation: The CT systems are not the principal means of guidance during invasive procedures, and needle orientation and advancement remain under physician control. Optional advanced-visualization applications require their own cleared standalone version, and feature availability varies across scanner models and configurations.
Clinical takeaway. Clinical role: The SOMATOM go and SOMATOM X platform CT systems with SOMARIS/10 syngo CT VB10 generate and process cross-sectional images from X-ray transmission data for trained staff to use as an aid in diagnosis, treatment and radiation therapy planning, and diagnostic or therapeutic interventions; the systems may also be used for low-dose lung cancer screening in high-risk populations.
Evidence takeaway. Evidence from the reviewed source record: FDA-reviewed support consists of non-clinical integration, functional, image-quality, phantom, and bench testing for the listed CT platforms with syngo CT VB10. The 510(k) summary does not describe an independent clinical outcomes study.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
The SOMATOM go and SOMATOM X platform CT systems with SOMARIS/10 syngo CT VB10 generate and process cross-sectional images from X-ray transmission data for trained staff to use as an aid in diagnosis, treatment and radiation therapy planning, and diagnostic or therapeutic interventions; the systems may also be used for low-dose lung cancer screening in high-risk populations.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
CT patient positioning and acquisition, image reconstruction, image evaluation, and optional post-processing support within diagnosis, treatment planning, radiation therapy planning, and intervention workflows.
X-ray transmission data acquired on the listed SOMATOM go and SOMATOM X single-source CT scanner systems; supported options include three-dimensional camera data for patient positioning and external respiratory trigger signals for specified workflows.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Reconstructed cross-sectional CT images in DICOM format for qualified-user review and compatible optional post-processing applications; supported features include positioning, reconstruction, image-evaluation, and intervention workflow outputs depending on system configuration.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Trained and qualified users in professional healthcare facilities, including physicians, radiologists, and technologists; diagnosis or treatment requires appropriately qualified U.S. users.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
The CT systems are not the principal means of guidance during invasive procedures, and needle orientation and advancement remain under physician control. Optional advanced-visualization applications require their own cleared standalone version, and feature availability varies across scanner models and configurations.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
FDA-reviewed support consists of non-clinical integration, functional, image-quality, phantom, and bench testing for the listed CT platforms with syngo CT VB10. The 510(k) summary does not describe an independent clinical outcomes study.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA-reviewed support consists of non-clinical integration, functional, image-quality, phantom, and bench testing for the listed CT platforms with syngo CT VB10. The 510(k) summary does not describe an independent clinical outcomes study.
EndpointCases in which the myNeedle Guide automatic needle-detection algorithm consistently detected the needle tip
PopulationA wide variety of CT scans used in manufacturer bench testing; sample size and clinical case composition were not reported in the 510(k) summary
Tested versionmyNeedle Guide with myNeedle Detection on supported K233650 systems with SOMARIS/10 syngo CT VB10
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
FDA recall Z-1239-2026 affects syngo.CT Brain Quantification, Vessel Hyperdensities, and ASPECTS applications on certain SOMATOM X.ceed systems. The FDA record states that the applications had not received 510(k) clearance, directs sites to stop using them in patient care, and says Siemens would remove them. FDA lists the recall as open and classified.
FDA source
Exact product version
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Exact SOMATOM X.ceed application match. The finding applies to the named applications and affected installations, not every function of the scanner platform.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: X-ray transmission data acquired on the listed SOMATOM go and SOMATOM X single-source CT scanner systems; supported options include three-dimensional camera data for patient positioning and external respiratory trigger signals for specified workflows.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The platform produces DICOM images and provides software interfaces for compatible optional post-processing applications, including previously cleared Siemens applications and other commercially distributed software.
Scope: Exact FDA submission. Confirm PACS routing, DICOM object support, interface versions, and each optional application's clearance and compatibility for the planned local configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: On-premises SOMATOM go or SOMATOM X scanner and computer platform running SOMARIS/10 syngo CT VB10, supplied ex-factory or as an optional upgrade for applicable existing systems.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Reconstructed cross-sectional CT images in DICOM format for qualified-user review and compatible optional post-processing applications; supported features include positioning, reconstruction, image-evaluation, and intervention workflow outputs depending on system configuration.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Reconstructed cross-sectional CT images in DICOM format for qualified-user review and compatible optional post-processing applications; supported features include positioning, reconstruction, image-evaluation, and intervention workflow outputs depending on system configuration.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
On-premises SOMATOM go or SOMATOM X scanner and computer platform running SOMARIS/10 syngo CT VB10, supplied ex-factory or as an optional upgrade for applicable existing systems.
The platform produces DICOM images and provides software interfaces for compatible optional post-processing applications, including previously cleared Siemens applications and other commercially distributed software.
Exact FDA submission
Checked 2026-09-02
Confirm PACS routing, DICOM object support, interface versions, and each optional application's clearance and compatibility for the planned local configuration.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Siemens Healthineers' cybersecurity page states that its Cybersecurity Management Service maintains a product security inventory of over 1,000 product versions and over 21,000 monitored software components, with security whitepapers, SBOMs and vulnerability assessments delivered via teamplay Fleet, and that it operates incident and vulnerability management.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Siemens Healthineers generally and does not scope these commitments to any specific product release; exact-release scope is not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact device classification names the subject device as a Computed Tomography X-ray System. Controlled directory normalization: Computed Tomography X-ray System -> CT/CTA.
The exact technical-characteristics section identifies the scanner principle as a Whole body X-Ray Computed Tomography Scanner; no narrower anatomy is inferred.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
22Fields reviewed
9Source classes checked
4Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 4 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 4 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-10-27 - Exact FDA submission
No public price or quote for the exact K233650 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Siemens SOMATOM go reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Enhanced Boundary for PCCT is a deep-learning CT processing function for improved soft-tissue delineation in routine head examinations with or without contrast.
Authorized purpose: Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.